Trending...
- California and European Commission discuss cooperation to accelerate the global transition to a carbon-neutral, resilient, and equitable future
- High5VR Announces World's First Fully Immersive First-Person VR Movie
- California: Governor Newsom announces appointments 3.23.2026
SAN DIEGO, Dec. 4, 2020 /PRNewswire/ -- Angiocrine Bioscience Inc., a clinical-stage biopharmaceutical company today announced that they have been selected by the American Society of Hematology (ASH) for an oral presentation on the preliminary results of a Phase 1b/2 study of AB-205 to prevent or reduce severe organ toxicities associated with high-dose therapy followed by autologous hematopoietic cell transplantation used with curative intent in patients with aggressive systemic lymphoma.
"Our investigators and Angiocrine are honored to be selected by ASH to present at its annual meeting this December," commented Paul Finnegan, MD, Angiocrine CEO. "We look forward to Dr. Michael Scordo's presentation of AB-205's efficacy and safety results from our Phase 1b/2 study as well as preparing for the upcoming Phase 3 registration study for this indication."
Session Name: 723. Clinical Allogeneic and Autologous Transplantation: Late Complications and Approaches to Disease Recurrence I
Session Date: Saturday, December 5, 2020
Session Time: 7:30 AM - 9:00 AM ET
Presentation Time: 7:45 AM ET
About Severe Regimen-Related Toxicities
High-dose therapy and autologous hematopoietic cell transplantation is considered a standard-of-care method to cure aggressive systemic lymphoma. High dose therapy effectively eradicates cancer cells but also damages healthy tissue, which can lead to severe toxicities. Most affected is the lining of the oral-gastrointestinal (GI) tract. The oral GI tract renews its mucosal lining every 3 to 7 days. Because of the collateral damage from high dose chemotherapy, the oral GI tract loses its ability to renew its lining, leading to inflammation (mucositis) and breakdown, causing nausea, vomiting and diarrhea that are refractory to available medications and require prolonged hospitalization. Severe oral GI toxicities can occur as frequently as 50% and cause profound misery to patients. The rates and severity increase with age and, thus, many older patients are turned away from the curative high dose therapy due to the risks of severe toxicities.
More on The Californer
About AB-205
AB-205 represents a new and unique approach to repairing damaged tissue through advanced cell-and-gene therapy. AB-205 consists of allogeneic (off-the shelf) 'universal' E-CEL® (human engineered cord endothelial) cells. Intravenous AB-205 is given after chemotherapy/radiation (high-dose therapy) conditioning and on the same day as autologous transplant. AB-205's immediate action repairs damaged tissue and thereby prevents (reduces) the extent of breakdown of tissues, which is the root cause of severe toxicities experienced by patients. Reducing or preventing severe toxicities means better quality of life and shorter stay in the hospital—i.e., savings to the healthcare system. AB-205 was recently granted both the Regenerative Medicine Advanced Therapy (RMAT) Designation and Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA). Angiocrine is actively planning to advance AB-205 into a multi-center single registration Phase 3 trial based on the results of the Phase 1b/2 study.
About Angiocrine Bioscience, Inc.
Angiocrine Bioscience is a clinical-stage biotechnology company developing a radically new way to biologically repair damaged and diseased tissues and organs. Based on its novel and proprietary E-CEL® platform, Angiocrine is developing multiple E-CEL therapies designed to repair damaged tissue from age-related degenerative disease of the musculoskeletal system; immune diseases that attack vessels, and ischemic diseases involving soft tissue, central nervous system and the heart.
More on The Californer
For additional information, please contact:
Angiocrine Bioscience, Inc.
John R. Jaskowiak
(877) 784-8496
[email protected]
SOURCE Angiocrine Bioscience, Inc.
Related Links
www.angiocrinebioscience.com
"Our investigators and Angiocrine are honored to be selected by ASH to present at its annual meeting this December," commented Paul Finnegan, MD, Angiocrine CEO. "We look forward to Dr. Michael Scordo's presentation of AB-205's efficacy and safety results from our Phase 1b/2 study as well as preparing for the upcoming Phase 3 registration study for this indication."
Session Name: 723. Clinical Allogeneic and Autologous Transplantation: Late Complications and Approaches to Disease Recurrence I
Session Date: Saturday, December 5, 2020
Session Time: 7:30 AM - 9:00 AM ET
Presentation Time: 7:45 AM ET
About Severe Regimen-Related Toxicities
High-dose therapy and autologous hematopoietic cell transplantation is considered a standard-of-care method to cure aggressive systemic lymphoma. High dose therapy effectively eradicates cancer cells but also damages healthy tissue, which can lead to severe toxicities. Most affected is the lining of the oral-gastrointestinal (GI) tract. The oral GI tract renews its mucosal lining every 3 to 7 days. Because of the collateral damage from high dose chemotherapy, the oral GI tract loses its ability to renew its lining, leading to inflammation (mucositis) and breakdown, causing nausea, vomiting and diarrhea that are refractory to available medications and require prolonged hospitalization. Severe oral GI toxicities can occur as frequently as 50% and cause profound misery to patients. The rates and severity increase with age and, thus, many older patients are turned away from the curative high dose therapy due to the risks of severe toxicities.
More on The Californer
- Pet Furniture Meets Interior Design: Wooffy Redefines the Role of Dog Homes in Modern Living Spaces
- City to Add No-Cost Preschool to West Facilities Center in West Long Beach
- Snell & Wilmer Attorneys Emily Cheung and Kina Wong Appointed Co-Leads of CALA-OC Young Lawyers Cmte
- Long Beach: El Dorado East Regional Park Offers Tips for Visitors on Easter Sunday, April 5
- Classified Employees of the Year Celebrated Across the Ventura County Community College District
About AB-205
AB-205 represents a new and unique approach to repairing damaged tissue through advanced cell-and-gene therapy. AB-205 consists of allogeneic (off-the shelf) 'universal' E-CEL® (human engineered cord endothelial) cells. Intravenous AB-205 is given after chemotherapy/radiation (high-dose therapy) conditioning and on the same day as autologous transplant. AB-205's immediate action repairs damaged tissue and thereby prevents (reduces) the extent of breakdown of tissues, which is the root cause of severe toxicities experienced by patients. Reducing or preventing severe toxicities means better quality of life and shorter stay in the hospital—i.e., savings to the healthcare system. AB-205 was recently granted both the Regenerative Medicine Advanced Therapy (RMAT) Designation and Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA). Angiocrine is actively planning to advance AB-205 into a multi-center single registration Phase 3 trial based on the results of the Phase 1b/2 study.
About Angiocrine Bioscience, Inc.
Angiocrine Bioscience is a clinical-stage biotechnology company developing a radically new way to biologically repair damaged and diseased tissues and organs. Based on its novel and proprietary E-CEL® platform, Angiocrine is developing multiple E-CEL therapies designed to repair damaged tissue from age-related degenerative disease of the musculoskeletal system; immune diseases that attack vessels, and ischemic diseases involving soft tissue, central nervous system and the heart.
More on The Californer
- House of Buneau Releases "Pretty Boy Heaven," A Cinematic Exploration of Beauty and Distance
- Bobotails Launches Premium Matching Harness Collections for Small & Medium Breed Dogs
- Homeowner Prep Announces Strategic Language Shift: Replacing "Renters" with "Future Homeowners" to Inspire Wealth-Building Mindsets
- LiposoMore™ Redefines Bioavailability: Joyful Nutritional Launches High-Performance Liposomal Vitamin C and Iron for the Global Supplement Market
- California: Governor Newsom strengthens bans on insider betting by state officials, takes aim at corruption fueled by Trump
For additional information, please contact:
Angiocrine Bioscience, Inc.
John R. Jaskowiak
(877) 784-8496
[email protected]
SOURCE Angiocrine Bioscience, Inc.
Related Links
www.angiocrinebioscience.com
Filed Under: Business
0 Comments
Latest on The Californer
- For April Fools' Day: A poem about The Secret to Happiness! The secret is "Don't Say Nuthin'"
- Long Beach: Meredith Reynolds Appointed as Acting Director of Technology and Innovation Department
- California: Governor Newsom announces CHP crackdown: 12,600 arrests, 6,400 stolen cars recovered, 25 million deadly fentanyl doses seized in two years
- Award-Winning REALTOR® Paige Coker Joins Corcoran DeRonja Real Estate
- License Plate Owner Lookup API Goes Live on RapidAPI and Postman Public Network
- Over 98% of crypto owners globally don't declare taxes, new report find
- TicTac Group acquires French EdTech company Distrisoft
- TL Foundation Supports Connect's 2026 Cool Companies to Strengthen San Diego's Innovation Economy
- Equestrian Expert Rominger Receives National Recognition Through the INDEPENDENT PRESS AWARD®!
- Scientology Network Celebrates International Day of Happiness with Global Marathon
- New Platform Helps Gig Workers Avoid Paying Taxes on Income They Never Received
- Comedian Marc Yaffee Headlines Willits High School Sober Grad Fundraiser Show
- California: Governor Newsom convenes leaders to confront crisis facing boys and men
- Governor Newsom launches campaign to recruit young men, and all Californians, to serve communities and gain job skills
- VCCCD Announces Ventura College Presidential Finalists
- Squeegex Expands Window Cleaning and Exterior Services Across 30+ San Diego Neighborhoods
- Long Beach: City Recognizes Tsunami Preparedness Week 2026: Know the Risk. Know the Route.
- Mark Dobosz Makes Donorassess.org Free To Every Nonprofit On The Planet
- THE DASH CAM: THINKWARE Launches Big Spring Sale on Select Dash Cam Models
- Genpak Announces Closure of Utah Manufacturing Facility